Dormancy in breast cancer

Banys, Malgorzata; Hartkopf, Andreas D.; Krawczyk, Natalia; Kaiser, Tatjana; Meier-Stiegen, F; Fehm, Tanja; Neubauer, Hans

doi:10.2147/bctt.s26431

Cited by 25 publications

(14 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor dormancy is considered to be one trigger of late recurrence [23]. Tumor dormancy describes a prolonged quiescent state in which tumor cells are present, but disease progression is not yet clinically apparent.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura¹,

Osako²,

Nishiyama³

et al. 2013

Oncology

9,355

View full text Add to dashboard Cite

Background: Breast cancer is associated with a relatively good prognosis. Prognostic factors examined to date are related to early recurrence while those related to late recurrence and their countermeasures remain unclear. Therefore, we examined the factors related to late recurrence. Patients and Methods: From January 1980 to August 2012, 4,774 patients who underwent primary treatment and estrogen (ER) and progesterone receptor (PgR) assessment were enrolled in this study. The patients were divided into two groups, those with a follow-up period <10 years and those without any recurrence at 10 years but who continued follow-up examinations. Recurrence occurred in 711 patients followed up for <10 years and in 51 patients for ≥10 years. Results: The overall 10-year cumulative disease-free survival rate was 79.5%, and the recurrence rate at ≥10 years was 5.8%. A multivariate analysis revealed that the factors related to late recurrence were PgR positivity and positive nodes. This result differed from that for early recurrence in terms of ER/PgR, Ki-67 index and p53 overexpression. Conclusion: PgR positivity and lymph node metastases significantly correlated with late recurrence. Therefore, it is important to evaluate appropriate measures such as treatment period and treatment regimen for hormone-sensitive patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura¹,

Osako²,

Nishiyama³

et al. 2013

Oncology

9,355

View full text Add to dashboard Cite

show abstract

“…While these models of dormancy are not mutually exclusive and might even coexist in the same patient, we will focus on cellular dormancy that is best supported by clinical evidence (Banys, Hartkopf, et al, 2012; Morrissey, Vessella, Lange, & Lam, 2015). Several studies showed that DTCs are frequently found in cancer patients with NED (Braun et al, 2005; Chery et al, 2014; Klein, 2009; Schardt et al, 2005), and the detection of DTCs in the bone marrow is associated with worse clinical outcome in many solid cancers (Braun et al, 2000; Hartkopf et al, 2014, 2015; Thorban, Rosenberg, Busch, & Roder, 2000; Wollenberg et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

The Relationship Between Dormant Cancer Cells and Their Microenvironment

Linde

Fluegen

Aguirre‐Ghiso

2016

Advances in Cancer Research

133

131

View full text Add to dashboard Cite

The majority of cancer deaths are due to metastases that can occur years or decades after primary tumor diagnosis and treatment. Disseminated tumor cells (DTCs) surviving in a dormant state in target organs appear to explain the timing of this phenomenon. Knowledge on this process is important as it might provide a window of opportunity to prevent recurrences by eradicating dormant DTCs and/or by maintaining DTCs in a dormant state. Importantly, this research might offer markers of dormancy for early monitoring of metastatic relapse. However, our understanding of the mechanisms underlying the regulation of entry into and exit from dormancy is still limited and crippling any therapeutic opportunity. While cancer cell-intrinsic signaling pathways have been linked to dormancy regulation, it is likely that these pathways and the switch controlling reactivation from dormancy are regulated by microenvironmental cues. Here we review and discuss recent findings on how the microenvironment regulates cancer dormancy and raise new questions that may help advance the field.

show abstract

“…Since patients with ovarian carcinoma rarely develop secondary bone metastases, bone marrow seems to serve as a temporary "compartment" for disseminated tumor cells, where they might stay dormant for prolonged periods of time [20,21]. Subsequently, they might be able to leave their homing site and cause metastatic growth or locoregional recurrence [6].…”

Section: Discussionmentioning

confidence: 99%

Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer

Banys-Paluchowski

Fehm

Neubauer

et al. 2020

Arch Gynecol Obstet

Self Cite

View full text Add to dashboard Cite

Purpose Presence of circulating tumor cells (CTCs) is associated with impaired clinical outcome in several solid cancers. Limited data are available on the significance of CTCs in gynaecological malignancies. The aims of the present study were to evaluate the dynamics of CTCs in patients with ovarian, fallopian tube and peritoneal cancer during chemotherapy and to assess their clinical relevance. Methods 43 patients with ovarian, fallopian tube and peritoneal cancer were included into this prospective study. Patients received chemotherapy according to national guidelines. CTC analysis was performed using the CellSearch system prior to chemotherapy, after three and six cycles. Results In 26% of the patients, ≥ 1CTC per 7.5 ml of blood was detected at baseline (17% of patients with de novo disease, compared to 35% in recurrent patients). Presence of CTCs did not correlate with other factors. After three cycles of therapy, CTC positivity rate declined to 4.8%. After six cycles, no patient showed persistent CTCs. Patients with ≥ 1 CTC at baseline had significantly shorter overall survival and progression-free survival compared to CTC-negative patients (OS: median 3.1 months vs. not reached, p = 0.006, PFS: median 3.1 vs. 23.1 months, p = 0.005). When only the subgroup with newly diagnosed cancer was considered, the association between CTC status and survival was not significant (OS: mean 17.4 vs. 29.0 months, p = 0.192, PFS: 14.3 vs. 26.9 months, p = 0.085). Presence of ≥ 1 CTC after three cycles predicted shorter OS in the entire patient cohort (p < 0.001). Conclusions Hematogenous tumor cell dissemination is a common phenomenon in ovarian, fallopian tube and peritoneal cancer. CTC status before start of systemic therapy correlates with clinical outcome. Chemotherapy leads to a rapid decline in CTC counts; further research is needed to evaluate the clinical value of CTC monitoring after therapy.

show abstract

Dormancy in breast cancer

Cited by 25 publications

References 75 publications

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

The Relationship Between Dormant Cancer Cells and Their Microenvironment

Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer

Contact Info

Product

Resources

About